Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adverum Biotechnlgs (ADVM)

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,524
  • Shares Outstanding, K 98,770
  • Annual Sales, $ 7,500 K
  • Annual Income, $ -145,540 K
  • 60-Month Beta 1.31
  • Price/Sales 15.54
  • Price/Cash Flow N/A
  • Price/Book 0.41
Trade ADVM with:

Options Overview Details

View History
  • Implied Volatility 138.31% ( -68.56%)
  • Historical Volatility 55.10%
  • IV Percentile 52%
  • IV Rank 7.41%
  • IV High 1,184.88% on 06/10/22
  • IV Low 54.59% on 08/11/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 127
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 22,738
  • Open Int (30-Day) 24,438

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.39
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +15.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8715 +33.10%
on 06/02/22
1.2300 -5.69%
on 06/28/22
+0.2794 (+31.73%)
since 06/01/22
3-Month
0.7954 +45.84%
on 05/16/22
1.3600 -14.71%
on 04/05/22
-0.1400 (-10.77%)
since 04/01/22
52-Week
0.7954 +45.84%
on 05/16/22
3.6600 -68.31%
on 07/12/21
-2.4400 (-67.78%)
since 07/01/21

Most Recent Stories

More News
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD

REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1650 (-2.92%)
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting

- OPTIC study of intravitreal gene therapy with ADVM-022 (AAV.7m8-aflibercept) for wet AMD shows therapeutic levels of aflibercept out to three years- New...

ADVM : 1.1650 (-2.92%)
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1650 (-2.92%)
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1650 (-2.92%)
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1650 (-2.92%)
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting

- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean...

ADVM : 1.1650 (-2.92%)
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022

Szilárd Kiss, M.D. to present new post-hoc analyses from the Phase 1 OPTIC Trial of ADVM-022 (AAV.7m8-aflibercept) in wet AMD...

ADVM : 1.1650 (-2.92%)
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

VYGR : 6.05 (+2.37%)
ADVM : 1.1650 (-2.92%)
TRVI : 2.91 (+3.56%)
AXLA : 2.12 (+4.43%)
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA

Company anticipates completing IND amendment process by mid-2022 to enable dosing of the first patient in the planned Phase 2 trial during Third Quarter of...

ADVM : 1.1650 (-2.92%)
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1650 (-2.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development,...

See More

Key Turning Points

3rd Resistance Point 1.3267
2nd Resistance Point 1.2733
1st Resistance Point 1.2367
Last Price 1.1650
1st Support Level 1.1467
2nd Support Level 1.0933
3rd Support Level 1.0567

See More

52-Week High 3.6600
Fibonacci 61.8% 2.5657
Fibonacci 50% 2.2277
Fibonacci 38.2% 1.8897
Last Price 1.1650
52-Week Low 0.7954

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar